BAUM CHARLES M — SEC Form 4 filings
SEC reporting owner CIK 1579824. 10 Form 4 filings on record with FilingPulse; latest filed 2026-06-22.
Transaction summary — filings shown
Covers all 10 filings on record, filed 2024-01-23 to 2026-06-22. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 24.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Mirati Therapeutics, Inc. (MRTX) | Founder, President, and CEO, Director | 1 | — | — | 11 |
| Poseida Therapeutics, Inc. (PSTX) | Director | 2 | — | — | 6 |
| Acrivon Therapeutics, Inc. (ACRV) | Director | 4 | — | — | 4 |
| PMV Pharmaceuticals, Inc. (PMVP) | Director | 3 | — | — | 3 |
Form 4 filings — BAUM CHARLES M
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-06-22 | 4 | Acrivon Therapeutics, Inc. (ACRV) | Grant/award (A): 20,275 (derivative) @ $0 | EDGAR |
| 2026-06-05 | 4 | PMV Pharmaceuticals, Inc. (PMVP) | Grant/award (A): 42,000 (derivative) @ $0 | EDGAR |
| 2026-05-20 | 4 | Acrivon Therapeutics, Inc. (ACRV) | Grant/award (A): 9,366 @ $0 | EDGAR |
| 2025-06-17 | 4 | Acrivon Therapeutics, Inc. (ACRV) | Grant/award (A): 20,275 (derivative) @ $0 | EDGAR |
| 2025-06-09 | 4 | PMV Pharmaceuticals, Inc. (PMVP) | Grant/award (A): 33,500 (derivative) @ $0 | EDGAR |
| 2025-01-08 | 4 | Poseida Therapeutics, Inc. (PSTX) | Code (U): 78,600 · Disposition to issuer (D): 57,000 (derivative) @ $0 · Disposition to issuer (D): 27,350 (derivative) @ $0 · Disposition to issuer (D): 27,350 (derivative) @ $0 | EDGAR |
| 2024-06-24 | 4 | Acrivon Therapeutics, Inc. (ACRV) | Grant/award (A): 20,275 (derivative) @ $0 | EDGAR |
| 2024-06-18 | 4 | Poseida Therapeutics, Inc. (PSTX) | Grant/award (A): 19,650 @ $0 · Grant/award (A): 27,350 (derivative) @ $0 | EDGAR |
| 2024-06-10 | 4 | PMV Pharmaceuticals, Inc. (PMVP) | Grant/award (A): 67,500 (derivative) @ $0 | EDGAR |
| 2024-01-23 | 4 | Mirati Therapeutics, Inc. (MRTX) | Disposition to issuer (D): 123,389 · Disposition to issuer (D): 94,057 · Disposition to issuer (D): 20,425 · Disposition to issuer (D): 100,273 (derivative) · Disposition to issuer (D): 69,258 (derivative) · Disposition to issuer (D): 81,458 (derivative) · +5 more | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1579824 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →